{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.1444.3.159","meta":{"versionId":"6","lastUpdated":"2021-05-21T01:00:57.000-04:00"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.159","version":"20210521","name":"Cabazitaxel Injectable","status":"active","date":"2021-05-21T01:00:57-04:00","publisher":"American Society of Clinical Oncology Steward","compose":{"include":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","concept":[{"code":"1001433","display":"1.5 ML cabazitaxel 40 MG/ML Injection"}]}]},"expansion":{"identifier":"urn:uuid:4ed1a712-fe9e-4a37-b0a8-4d6f0e593071","timestamp":"2022-06-10T05:18:44-04:00","total":1,"offset":0,"parameter":[{"name":"count","valueInteger":1000},{"name":"offset","valueInteger":0}],"contains":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","code":"1001433","display":"1.5 ML cabazitaxel 40 MG/ML Injection"}]}}